Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection

Yang, Yao‐Hsu; Chen, Wen‐Cheng; Tsan, Yu‐Tse; Chen, Mei‐Jyh; Shih, Wei-Tai; Tsai, Ying‐Huang; Chen, Pau‐Chung

doi:10.1016/j.jhep.2015.07.006

Cited by 82 publications

(82 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Coincident findings were described in a population-based retrospective cohort study in Taiwan, examining database information from 226,856 HCV patients, where a dose-dependent reduction on cirrhosis development was seen in statin users, with a higher reduction in cirrhosis emergence in patients with higher statins cumulative daily doses (adjusted HR 0.13) [47]. Multiple confounders could not be completely addressed as the statin users group had increased use of other cardiovascular medications (e.g., metformin, aspirin, angiotensin-converting enzyme inhibitors) and higher comorbidity.…”

Section: Clinical Studiesmentioning

confidence: 81%

“…Increasing amount of data have been accumulated focusing on the use of statins in cirrhotic patients regardless of etiology, additional to some of the abovementioned studies in HBV and HCV patients [47, 48]. A retrospective study by Kumar S. et al evaluated statin use in 81 cirrhotic patients matched 1:2 to look for increased mortality or decompensation with a mean follow-up of 36 months, including most cirrhotic patients at an early stage (Child-Pugh A).…”

Section: Clinical Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects

Vargas

Arrese

Shah

et al. 2017

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Purpose of review The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis. Recent findings Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention. Summary In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.

show abstract

Section: Clinical Studiesmentioning

confidence: 81%

Section: Clinical Studiesmentioning

confidence: 99%

Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects

Vargas

Arrese

Shah

et al. 2017

Curr Gastroenterol Rep

View full text Add to dashboard Cite

show abstract

“…Five studies reported risk of development of cirrhosis (or progression of fibrosis) in patients with baseline non-cirrhotic CLDs 35, 39–41, 43 . In three studies, diagnosis of cirrhosis (or fibrosis progression) was ascertained based on a combination of administrative claims codes and calculated serum fibrosis markers (FIB-4 or APRI); one study was a post-hoc analysis of the HALT-C trial included patients with paired liver biopsies, with fibrosis progression defined based on increase in Ishak fibrosis stage by ≥ 2.…”

Section: Resultsmentioning

confidence: 99%

Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis

Kim

Loomba

Prokop

et al. 2017

Clinical Gastroenterology and Hepatology

138

112

View full text Add to dashboard Cite

Background & Aims Statins have been variably shown to decrease risk and complications of chronic liver diseases (CLDs). We performed a systematic review and meta-analysis to evaluate the association between statins and risk of cirrhosis and related complications in patients with CLDs. Methods Through a systematic literature search up to March 2017, we identified 13 studies (3 randomized trials, 10 cohort studies) in adults with CLDs, reporting the association between statin use and risk of development of cirrhosis, decompensated cirrhosis, improvements in portal hypertension, or mortality. Pooled relative risk (RR) estimates with 95% CIs were calculated using random effects model. GRADE criteria were used to assess quality of evidence. Results Among 121,058 patients with CLDs (84.5% with hepatitis C), 46% were exposed to statins. In patients with cirrhosis, statin use was associated with 46% lower risk of hepatic decompensation (4 studies; RR, 0.54; 95% CI, 0.46–0.62; I2=0%; moderate quality evidence), and 46% lower mortality (5 studies; RR, 0.54; 95% CI, 0.47–0.61; I2=10%; moderate quality evidence). In patients with CLD without cirrhosis, statin use was associated with a non-significant (58% lower) risk of development of cirrhosis or fibrosis progression (5 studies; RR, 0.42; 95% CI, 0.16–1.11; I2=99%; very low quality evidence). In 3 randomized controlled trials, statin use was associated with 27% lower risk of variceal bleeding or progression of portal hypertension (hazard ratio, 0.73; 95% CI, 0.59–0.91; I2=0%; moderate quality evidence). Conclusion Based on a systematic review and meta-analysis, statin use is probably associated with lower risk of hepatic decompensation and mortality, and might reduce portal hypertension, in patients with CLDs. Prospective observational studies and randomized controlled trials are needed to confirm this observation.

show abstract

“…Their study also discovered that an accumulated dose of statins of <215.4 DDD reduced HCC risk by 38% among patients, compared with those who did not receive statins. They concluded that an accumulated dose of statins of >215.4 DDD was not associated with any significant differences, which they similarly attributed to an inadequate sample size [2][3][4]. However, it was determined in the present study that cumulative daily dose, cumulative days, and average daily dose were all linearly correlated (P<0.001) regarding the correlation between statin drug usage and HCC risk among the patients with DM and either hepatitis B or hepatitis C. One possible reason for this discrepancy, in comparison to the study by Chiu et al [1] did not focus solely on whether receiving statin drugs could reduce HCC risk among patients with DM.…”

Section: Discussionmentioning

confidence: 99%

Ectopic Expression of DSCR1 in Conjunction with NDV Infection Reduces VEGF and Induces Apoptosis in Lung Cancer A549 Cell Line

Rad¹,

Boroujeni²,

Aleyasin³

2019

J Cancer Sci Ther

View full text Add to dashboard Cite

Objectives: To determine the relationship between the dose effect of Statin and the risk of HCC. Methods:This study was a case-control study. All participants were ≧ 50 years of age and were diagnosed with diabetes (ICD-9250.0x 0, 205.0 × 2) and were treated with an anti-diabetic agent for at least for 3 months according to the NHID, LHID2010 (longitudinal health insurance database 2010). We captured the use of a Statin before the index date in patients with type II diabetes. Patients diagnosed with a hepatoma (ICD-9:155) were defined as the case group. Results

show abstract

Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection

Cited by 82 publications

References 29 publications

Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects

Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects

Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis

Ectopic Expression of DSCR1 in Conjunction with NDV Infection Reduces VEGF and Induces Apoptosis in Lung Cancer A549 Cell Line

Contact Info

Product

Resources

About